Back to Search
Start Over
Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial
- Source :
- JNCI Cancer Spectrum
- Publication Year :
- 2020
- Publisher :
- Oxford University Press (OUP), 2020.
-
Abstract
- Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin’s anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual low-dose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12 months of treatment (-0.12 mm [SD = 1.55 mm] and +0.30 mm [SD= 2.54 mm], respectively; 2-sided P = .33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.
- Subjects :
- Cancer Research
medicine.medical_specialty
Aspirin
business.industry
Phases of clinical research
Cancer
Nodule (medicine)
Brief Communication
medicine.disease
Placebo
Gastroenterology
Oncology
Internal medicine
medicine
Clinical endpoint
medicine.symptom
AcademicSubjects/MED00010
Lung cancer
business
Lung cancer screening
medicine.drug
Subjects
Details
- ISSN :
- 25155091
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- JNCI Cancer Spectrum
- Accession number :
- edsair.doi.dedup.....8631b7de3800c82890fa2afa20cb4e17